Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
Logica, an offering from Charles River and Valo Health, will be used to discover first-in-class therapeutics against high value targets in the Related Sciences portfolio
Charles River Laboratories International, and Related Sciences (“RS”), a data science-driven drug discovery firm, announced a multi-program collaboration agreement to apply Logica across several previously undrugged targets in the RS portfolio. Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized assets.
Read More about AiThority: Developing Responsible AI Solutions for Healthcare: A CTO’s Perspective
“Logica’s combination of advanced AI/ML and state-of-the-art hit finding approaches, within a unique risk-sharing business model, pairs beautifully with Related Sciences’ data science-driven, multi-technology approach to drug discovery.”
Under the collaboration, RS will work closely with the Charles River and Valo Health teams to deploy Logica to discover valuable new medicines to address key unmet needs across a range of disease areas, including cancer immunotherapy, autoimmunity, and inflammatory diseases.
“Partnering with the team at Related Sciences, we are excited to deploy Logica in the hunt for first-in-class therapeutics,” said Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s unique platform, which combines AI/machine learning (ML)-enabled in silico discovery, high-powered DNA-encoded libraries, and traditional screening techniques, has the capability to accelerate the drug discovery and development pipeline, transforming a target to a candidate in just over two years.”
AiThority Insights: Can Artificial Intelligence Detect Business Logic Attacks Early?
“Across our growing portfolio, Related Sciences brings together specialized technologies and orthogonal screening approaches that can maximize our chances of discovering transformational new medicines against high value targets,” said Adam Kolom, Founder and CEO of Related Sciences. “Logica’s combination of advanced AI/ML and state-of-the-art hit finding approaches, within a unique risk-sharing business model, pairs beautifully with Related Sciences’ data science-driven, multi-technology approach to drug discovery.”
Logica: Redefining Small Molecule Drug Discovery’s Gold Standard
In 2022, Charles River and Valo Health launched Logica, leveraging the AI-powered Valo Opal Computational PlatformTM and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination. Logica is offered as a fully managed, risk-sharing model, with most of the client cost tied to success.
Logica utilizes industry-leading predictive models, chemical design, and synthesis capabilities, DNA-encoded libraries, in silico high throughput screening from Valo’s Opal Computational Platform as well as Charles River’s leading capabilities in all aspects of discovery optimization including high throughput screening, medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission, joining together for the first time to create a computation-powered, unified target-to-candidate offering.
Latest AiThority Insights : “What Will Happen to All the Horses?” – Surviving the Coming AI Revolution
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.